These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20167911)

  • 1. A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial.
    Mandava P; Kalkonde YV; Rochat RH; Kent TA
    Stroke; 2010 Apr; 41(4):765-70. PubMed ID: 20167911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex.
    Mandava P; Murthy SB; Munoz M; McGuire D; Simon RP; Alexandrov AV; Albright KC; Boehme AK; Martin-Schild S; Martini S; Kent TA
    Stroke; 2013 Jun; 44(6):1525-31. PubMed ID: 23674524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
    Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
    Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.
    Khatri P; Kleindorfer DO; Yeatts SD; Saver JL; Levine SR; Lyden PD; Moomaw CJ; Palesch YY; Jauch EC; Broderick JP
    Stroke; 2010 Nov; 41(11):2581-6. PubMed ID: 20814000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
    Brown DL; Johnston KC; Wagner DP; Haley EC
    Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
    Osaki M; Miyashita F; Koga M; Fukuda M; Shigehatake Y; Nagatsuka K; Minematsu K; Toyoda K
    Eur J Neurol; 2014 Mar; 21(3):411-8. PubMed ID: 24200315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reperfusion after 4.5 hours reduces infarct growth and improves clinical outcomes.
    Picanço MR; Christensen S; Campbell BC; Churilov L; Parsons MW; Desmond PM; Barber PA; Levi CR; Bladin CF; Donnan GA; Davis SM;
    Int J Stroke; 2014 Apr; 9(3):266-9. PubMed ID: 24256139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.
    Salam KA; Ummer K; Pradeep Kumar VG; Noone ML
    Int J Stroke; 2014 Jun; 9(4):426-8. PubMed ID: 23981667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of racial differences on outcomes after thrombolytic therapy in acute ischemic stroke.
    Mishra NK; Mandava P; Chen C; Grotta J; Lees KR; Kent TA;
    Int J Stroke; 2014 Jul; 9(5):613-7. PubMed ID: 24148895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postthrombolysis outcomes in acute ischemic stroke patients of Asian race-ethnicity.
    Mishra NK; Chan BP; Teoh HL; Meng CH; Lees KR; Chen C; Sharma VK;
    Int J Stroke; 2013 Oct; 8 Suppl A100():95-9. PubMed ID: 23490069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.